Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and extend cash runway to Q4 2027. Read more here.

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027.

Explore NASA's 25 new NOIS contracts and how crowdsourcing and collaboration can potentially address space exploration challenges.

Dr. James McCaffrey from Microsoft Research presents a complete end-to-end demonstration of computing a matrix inverse using the Newton iteration algorithm. Compared to other algorithms, Newton ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. | Recursion is ...

40th iteration of exercise TRADEWINDS 25 unites 26 nations promoting security in the Western Hemisphere By Sgt. Joshua Taeckens April 30, 2025 ...

Space Contracts for SSC’s next iteration of MEO missile tracking satellites delayed "Unfortunately, we were, we were slowed down a bit by uncertainty in our budget," said SSC's Col. Rob Davis ...

Techstars Atlanta, an accelerator program for some of the city’s most promising startups, is changing its model from being backed solely by a corporate sponsor to being community supported, the ...

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $6.48, denoting a -1.52% change from the preceding trading day.